ADHD vs Autism Spectrum Disorder: Key Differences

ADHD and autism spectrum disorder are separate diagnoses. ADHD is defined by inattention and hyperactivity-impulsivity¹, autism by lasting differences in social communication plus restricted, repetitive behaviors². They often occur together: 28% of autistic people also have ADHD in a meta-analysis of 96 studies³, and 1.2% of all US children aged 3 to 17 had both in a survey of 88,051 children⁴.

Neither condition has a single confirming test^{5, 2}, so this guide compares the criteria, the research on where they overlap, and the evidence for treatments. Our evidence pages on ADHD and autism spectrum disorder cover supplements in more detail.

ADHD is a pattern of attention, activity and impulse-control problems. Autism is a pattern of social-communication differences with restricted, repetitive behavior.

ADHD symptoms show up in one of three presentations¹:

• Predominantly inattentive: trouble organizing or finishing tasks, following instructions, and keeping track of daily routines.
• Predominantly hyperactive-impulsive: fidgeting, talking a lot, restlessness, interrupting and trouble waiting a turn.
• Combined: both sets of symptoms are equally present.

The presentation can change over time¹.

The DSM-5 criteria for autism require persistent deficits in each of three areas of social communication and interaction: social-emotional reciprocity, nonverbal communication (including eye contact and body language), and developing and keeping relationships². They also require at least two of four restricted, repetitive patterns²:

• Repetitive movement, objects or speech, such as lining up toys or echolalia.
• Insistence on sameness, such as extreme distress at small changes and trouble with transitions.
• Highly fixated interests that are unusual in intensity or focus.
• Unusual sensory reactions, such as a strong response to certain sounds or textures.

Autism symptoms must begin in early development and cause real impairment, and severity is rated in three levels of support need².

No. ADHD has its own criteria and its own diagnosis. CDC lists autism spectrum disorder among the conditions that most commonly occur alongside ADHD⁶, which treats them as two conditions rather than one being a form of the other.

The two do share biology. A genome-wide analysis of the two disorders found seven genetic loci shared by both and five that differentiate them, and all five differentiating loci pointed in opposite directions in ADHD and autism⁷.

The word "spectrum" also means different things. ADHD is described by three presentations¹, while autism is rated on three levels of support need².

Yes, and it is common. In the 2016-2018 National Survey of Children's Health, about 1.2% of children aged 3 to 17 (740,816 children) had parent-reported autism and ADHD together⁴. Co-occurrence was more likely in boys, in older children and in those reported to be in poor health⁴.

A Swedish register study of 1,899,654 people born from 1987 to 2006 found that people with autism had much higher odds of ADHD (odds ratio 22.33, 95% CI 21.77-22.92), and the link was stronger in autism without intellectual disability⁸. Relatives of autistic people also had higher ADHD risk, and the link was stronger in identical twins (odds ratio 17.77) than in fraternal twins (4.33) or full siblings (4.59)⁸. That pattern points to shared genetic risk.

People diagnosed with both carried genetic predisposition for both disorders in the cross-disorder analysis⁷. Getting both diagnoses can take longer: in a survey of 677 Australian caregivers, the delay between first developmental concerns and diagnosis was longer for children with both conditions than for either alone⁹.

Social cognition, especially theory of mind, is more impaired in autism, while ADHD shows milder deficits. A meta-analysis pooled 44 studies comparing 1,999 people with ADHD to 1,725 controls and 17 studies comparing 772 people with ADHD to 710 with autism¹⁰. Emotion recognition (d = 0.40-0.44) and theory of mind (d = 0.43) were impaired in ADHD, but deficits were more pronounced in autism, especially theory of mind¹⁰. ADHD performance sat between autism and healthy controls¹⁰.

The pattern also differs by skill. In 225 Italian children aged 8 to 16 (66 with ADHD, 51 with level 1 autism, 108 without a diagnosis), children with ADHD had more trouble with social performance, while autistic children had more trouble with social perception and some aspects of social knowledge¹¹.

In adults with ADHD, social-cognition deficits were very subtle or not significant, which suggests they may ease with age¹⁰.

Attention, movement and sensory problems appear in both conditions, so one sign rarely settles the question. These are the ones people ask about most.

• Focus and executive function: a meta-analysis of 36 studies found no difference between ADHD and autism on neuropsychological tests (d = 0.02), but ADHD was rated worse on everyday questionnaires (d = -0.34)¹². Children with both conditions looked more like the ADHD-only group and had more difficulty than the autism-only group¹².
• Sensory differences: in 495 autistic people and 461 people with ADHD, the same five sensory profiles appeared in both groups¹³. In 61 autistic youth aged 6 to 17, sensory sensitivity predicted autistic traits even after controlling for ADHD symptoms, age, IQ and sex¹⁴. Sensory problems alone therefore do not separate the conditions. Whether sensitivity is specific to autism is preliminary, because the second study included only autistic participants.
• Movement and stimming: repeated movements or speech count toward the autism criteria², while squirming and fidgeting are listed among ADHD signs¹. Both involve movement, so a clinician looks at the whole pattern.
• Eye contact and nonverbal cues: abnormal eye contact and body language are named in the autism criteria². They are not on CDC's list of ADHD signs¹.
• Routines and change: insistence on sameness and distress at small changes are an autism criterion². Trouble resisting temptation and waiting a turn are on the ADHD list¹.

They use structured history and observation. For ADHD, there is no single test, and sleep disorders, anxiety, depression and some learning disabilities can look similar⁵. The American Academy of Pediatrics advises collecting reports from parents, teachers and other caregivers about behavior at home, at school and with peers⁵.

For autism, no single tool should be the basis for diagnosis. Assessment relies on caregivers' descriptions of development and a professional's observation of behavior, measured against the DSM-5 criteria².

Because no single test or tool is enough, a quiz alone cannot settle the question. If you are unsure which condition is behind a pattern, ask the clinician to evaluate for both, and bring:

• Examples from several settings, such as home, school and with friends.
• Early history, since autism symptoms must start in early development².
• Other conditions, because anxiety, sleep and learning problems can mimic ADHD⁵.

CDC adds that the American Academy of Pediatrics recommends screening every child with ADHD for other disorders and concerns⁶.

The research here is thin. One survey of 677 caregivers found that the delay to an autism diagnosis was longer for females with autism, and for females with both autism and ADHD, than for males⁹. The authors note that the reasons for the delay need further study⁹. Most of those caregivers (594 of 677) were recruited through social media and reported the diagnostic process themselves, so treat the result as a signal rather than a precise figure.

For adults, CDC notes that ADHD signs start in childhood and can continue into adulthood but may look different¹. Social-cognition differences in ADHD are subtler in adults¹⁰.

Emotional dysregulation, meaning difficulty regulating emotions as circumstances change, is more severe in autism than in other clinical groups. A meta-analysis found elevated emotion dysregulation in autistic people compared with both neurotypical people and other clinical populations¹⁵.

In a clinic sample of 123 psychiatrically referred autistic youth, 82% had a positive emotional-dysregulation profile on the Child Behavior Checklist versus 53% of youth with ADHD, and 44% versus 15% had the severe profile¹⁶. Because these youth were referred for psychiatric care, the rates will not apply to every autistic child.

Co-occurring mental health conditions are the best-quantified burden in the studies we reviewed. A meta-analysis of 35 studies in adults with autism pooled current and lifetime prevalence at 27% and 42% for any anxiety disorder, and 23% and 37% for depressive disorder¹⁷.

A second meta-analysis of 96 studies across all ages pooled prevalence at 28% for ADHD, 20% for anxiety disorders, 13% for sleep-wake disorders and 11% for depressive disorders³. Estimates were higher in clinic-based samples than in population-based ones³, and the adult review notes heavy reliance on clinical samples, so community rates may differ¹⁷.

Possibly, for hyperactivity, in short trials of children who tolerated the drug. A Cochrane review pooled four crossover trials of methylphenidate in 113 children aged 5 to 13 with autism. Each dose was given for one week¹⁸. High-dose methylphenidate (0.43 to 0.60 mg/kg per dose) lowered teacher-rated hyperactivity (standardized mean difference -0.78, 95% CI -1.13 to -0.43)¹⁸. The authors found no evidence that it harmed core autism symptoms or improved social interaction¹⁸.

Safety data are weak. Reduced appetite was the only side effect significantly more likely on treatment, and the adverse-event evidence is very low quality because trials were short and excluded children who could not tolerate a test dose¹⁸.

A later meta-analysis of 25 randomized trials in people under 25 found that methylphenidate reduced parent-rated hyperactivity (standardized mean difference -0.63) and inattention (-0.36), and atomoxetine reduced parent-rated inattention (-0.54)¹⁹. The authors rated the evidence for all interventions as low or very low quality¹⁹.

Medication is also not the starting point for every child. CDC reports that the American Academy of Pediatrics recommends parent training in behavior management as the first treatment for children with ADHD under 6, and medication combined with behavior therapy from age 6²⁰. Whether medication is right for a particular child is a prescriber's decision.

Mostly no, with sleep as the clearest exception. None of these replaces an evaluation or a prescribed treatment.

Omega-3 for ADHD

A 2023 Cochrane review of 37 trials with more than 2,374 children found high-certainty evidence that polyunsaturated fatty acids had no effect on parent-rated total ADHD symptoms (standardized mean difference -0.08, 95% CI -0.24 to 0.07; 16 studies, 1,166 participants)²¹. Inattention and hyperactivity-impulsivity scores did not differ from placebo either, and side effects were likely similar²¹. Our omega-3 for ADHD page covers this evidence.

Omega-3 for autism

A meta-analysis of five randomized trials in 183 children with autism found no firm benefit. Parents rated lethargy as improved in two trials, but ratings of externalizing behavior and social skills worsened on other scales, and the authors concluded the data did not show a benefit²². A later umbrella review of seven meta-analyses found a small reduction in hyperactivity in children aged 8 or younger (effect size -0.30), and an increase in stereotypy at doses of 1,000 mg/day or less (effect size 0.19)²³. The evidence is mixed and the trials are small. See omega-3 for autism spectrum disorder.

Melatonin for sleep

Sleep problems are where supplements have the best support. A meta-analysis of 13 randomized trials (682 children with neurodevelopmental disorders) found melatonin added 48.26 minutes of total sleep time (9 trials) and cut the time to fall asleep by 28.97 minutes (11 trials), with no medication-related serious adverse events reported²⁴. The authors rated the evidence as limited by heterogeneity and inconsistency²⁴.

In 125 children and adolescents (96.8% with autism), a prolonged-release pediatric melatonin minitablet (2 to 5 mg) added 32.43 minutes more nightly sleep than placebo after 13 weeks²⁵. That is a prescription-style pediatric formulation, so the result may not carry over to over-the-counter products. In 105 children aged 6 to 12 with ADHD and sleep-onset insomnia, 3 or 6 mg advanced sleep onset by 26.9 minutes versus a 10.5-minute delay on placebo, but did not change behavior, cognition or quality of life²⁶. See our melatonin page.

Supplements in this guide

• Omega-3 Fatty Acids
• Melatonin

Children are the group most affected, and the cautions are practical.

• Do not replace a prescribed ADHD medicine with a supplement. Omega-3 showed no effect on parent-rated ADHD symptoms²¹.
• ADHD medicines have trade-offs. CDC lists difficulty sleeping and loss of appetite as stimulant side effects, and advises talking with the provider about side effects before starting²⁰. In autistic children, appetite loss was much more likely on methylphenidate (risk ratio 8.28)¹⁸, and methylphenidate showed a nonsignificant higher risk of dropout from side effects¹⁹.
• Atomoxetine carries a boxed warning. Its label says it increased the risk of suicidal ideation in short-term studies in children and adolescents with ADHD²⁷.
• Melatonin products can be mislabeled. In a 2023 study, 22 of 25 over-the-counter melatonin gummies were inaccurately labeled, with 74% to 347% of the labeled amount²⁸.
• Melatonin needs safe storage and supervision. Keep it out of children's reach: an estimated 11,000 emergency department visits from 2019 to 2022 involved unsupervised ingestion by children 5 and younger²⁸. People with epilepsy or on blood thinners need medical supervision, and long-term safety information is lacking²⁸.
• Melatonin causes sleepiness. Somnolence was reported more often than with placebo in the autism trial²⁵. Behavioral sleep approaches are the usual first step²⁸.
• Omega-3 findings in autism are unconfirmed signals. Parent ratings of externalizing behavior worsened on one scale in two small autism trials, although adverse effects overall were similar to placebo²². A stimulant interaction check also matters: see our guide to Adderall and supplements.

Use a simple decision rule.

• If attention, restlessness and impulsivity dominate, ask for an ADHD evaluation, and ask the clinician to check for autism and for look-alike conditions such as sleep or anxiety problems⁵.
• If social communication, rigid routines and fixated interests dominate, ask for an autism evaluation, and ask about ADHD, which was present in 28% of autistic people in a meta-analysis of 96 studies³.
• If both patterns are present, say so. Having both is linked to a longer path to diagnosis⁹, and the combined group needs both conditions assessed.
• If sleep is poor, raise it separately. Melatonin has randomized-trial support in autism and ADHD^{24, 26}, and sleep is worth treating whatever the label.

For broader context, see our guide to mental health and the pages on anxiety and poor sleep quality.

We searched PubMed through a research-paper index for studies on ADHD and autism overlap, genetics, social cognition, executive function, sensory processing, diagnosis, medication, omega-3 and melatonin. We read 21 journal abstracts, 4 CDC pages, one NIH fact sheet and one drug label, and cited all of them. We prioritized Cochrane reviews, meta-analyses and large registers over single small trials.

The evidence cannot tell us how ADHD and autism differ in adults and women in detail, and the treatment trials in autism are small and mostly in children. This article was written on November 1, 2026 and does not replace a clinical evaluation.

1. Centers for Disease Control and Prevention. Symptoms of ADHD. https://www.cdc.gov/adhd/signs-symptoms/index.html
2. Centers for Disease Control and Prevention. Clinical Testing and Diagnosis for Autism Spectrum Disorder (DSM-5 diagnostic criteria). https://www.cdc.gov/autism/hcp/diagnosis/index.html
3. Lai MC, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819-829. doi:10.1016/S2215-0366(19)30289-5
4. Casseus M. Prevalence of co-occurring autism spectrum disorder and attention deficit/hyperactivity disorder among children in the United States. Autism. 2022;26(6):1591-1597. doi:10.1177/13623613221083279
5. Centers for Disease Control and Prevention. Diagnosing ADHD. https://www.cdc.gov/adhd/diagnosis/index.html
6. Centers for Disease Control and Prevention. Other Concerns and Conditions with ADHD. https://www.cdc.gov/adhd/other-topics/other-concerns-conditions.html
7. Mattheisen M, et al. Identification of shared and differentiating genetic architecture for autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups. Nat Genet. 2022;54(10):1470-1478. doi:10.1038/s41588-022-01171-3
8. Ghirardi L, et al. The familial co-aggregation of ASD and ADHD: a register-based cohort study. Mol Psychiatry. 2018;23(2):257-262. doi:10.1038/mp.2017.17
9. Knott R, et al. Age at diagnosis and diagnostic delay across attention-deficit hyperactivity and autism spectrums. Aust N Z J Psychiatry. 2024;58(2):142-151. doi:10.1177/00048674231206997
10. Bora E, et al. Meta-analysis of social cognition in attention-deficit/hyperactivity disorder (ADHD): comparison with healthy controls and autistic spectrum disorder. Psychol Med. 2016;46(4):699-716. doi:10.1017/S0033291715002573
11. Crisci G, et al. Social Functioning in Children and Adolescents with ADHD and Autism Spectrum Disorder: A Cross-Disorder Comparison. J Clin Child Adolesc Psychol. 2024;53(3):489-502. doi:10.1080/15374416.2024.2330479
12. Ceruti C, et al. Comparing Executive Functions in Children and Adolescents with Autism and ADHD-A Systematic Review and Meta-Analysis. Children (Basel). 2024;11(4). doi:10.3390/children11040473
13. Scheerer NE, et al. Transdiagnostic Patterns of Sensory Processing in Autism and ADHD. J Autism Dev Disord. 2024;54(1):280-292. doi:10.1007/s10803-022-05798-3
14. Masters EC, et al. Brief Report: Sensory Features Associated with Autism After Controlling for ADHD Symptoms. J Autism Dev Disord. 2025;55(7):2578-2586. doi:10.1007/s10803-023-06046-y
15. McDonald RG, et al. Emotion dysregulation in autism: A meta-analysis. Autism. 2024;28(12):2986-3001. doi:10.1177/13623613241257605
16. Joshi G, et al. High Risk for Severe Emotional Dysregulation in Psychiatrically Referred Youth with Autism Spectrum Disorder: A Controlled Study. J Autism Dev Disord. 2018;48(9):3101-3115. doi:10.1007/s10803-018-3542-9
17. Hollocks MJ, et al. Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis. Psychol Med. 2019;49(4):559-572. doi:10.1017/S0033291718002283
18. Sturman N, et al. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev. 2017;11(11):CD011144. doi:10.1002/14651858.CD011144.pub2
19. Rodrigues R, et al. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J Child Psychol Psychiatry. 2021;62(6):680-700. doi:10.1111/jcpp.13305
20. Centers for Disease Control and Prevention. Treatment of ADHD. https://www.cdc.gov/adhd/treatment/index.html
21. Gillies D, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2023;4(4):CD007986. doi:10.1002/14651858.CD007986.pub3
22. Horvath A, et al. ω-3 Fatty Acid Supplementation Does Not Affect Autism Spectrum Disorder in Children: A Systematic Review and Meta-Analysis. J Nutr. 2017;147(3):367-376. doi:10.3945/jn.116.242354 Our study summary.
23. Abbasi H, et al. Impact of omega-3 fatty acid supplementation on clinical manifestations in autism spectrum disorders: an umbrella review of meta-analyses. Nutr Res Rev. 2025;38(2):546-557. doi:10.1017/S0954422424000325
24. Abdelgadir IS, et al. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103(12):1155-1162. doi:10.1136/archdischild-2017-314181
25. Gringras P, et al. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(11):948-957.e4. doi:10.1016/j.jaac.2017.09.414
26. Van der Heijden KB, et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233-41. doi:10.1097/01.chi.0000246055.76167.0d
27. DailyMed. Strattera (atomoxetine hydrochloride) capsule: prescribing information, boxed warning on suicidal ideation in children and adolescents. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a7584b5-524d-4726-86a2-1b08e422f60e
28. National Center for Complementary and Integrative Health. Melatonin: What You Need To Know. https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know